Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price ...

Atalanta aims to create disease-modifying therapies by silencing certain genes in the central nervous system, including in the brain and spinal cord.

Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million Series B financing to ...

The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

This review focuses on intergenerational and transgenerational epigenetic inheritance in different plants, animal species and ...

Understanding the reprogramming of gene expression and metabolism is critical for the success of somatic embryogenesis-based plant tissue regeneration. Here, the authors report single-cell RNA ...

(NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing ...

Canadian groups who study and advocate for free expression have mixed feelings on Meta's changes to what is automatically considered "hateful" conduct on social media platforms like Facebook and ...